TREM2, Aviva Systems Biology, ARP49413_P050

Our team has carried out deep research in the published scientific literature to identify papers and reports using antibodies directed against human Triggering receptor expressed on myeloid cells 2 (TREM2) and followed up by extraction and evaluation of the available data to assess its performance according to pAbmAbs rating criteria.

YCharOS is here conducting a large head-to-head study comparing 14 commercial research antibodies against human Triggering receptor expressed on myeloid cells 2 encoded by the TREM2 gene

The collection of antibodies was tested using THP-1 WT and TREM2 KO cells in the applications WB (WT and KO cell medium/20 µg protein), IP (WT cell lysate) and IF (WT and KO cells) according to YCharOS standard protocols (see reference).

In WB (1:1000 ab dilution) ARP49413_P050 detected several bands (>7) in both genotypes, none of which were specific to WT cell lysate. A faint band was detected following IP (2 µg Ab used). In IF (1:500 ab dilution) a more intense staining was observed in WT cells compared to KO showing some background.

We highly encourage other scientists to share their observations.